This is a summary of the European public assessment report (EPAR) for Vosevi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vosevi. For practical information about using Vosevi, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg. (see sections 4.2, 4.4 and 5.1).
Therapeutic Area (MeSH)
ATC Code
J05A
ATC Item
直接作用的抗病毒药
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Sofosbuvir | N/A | 索磷布韦 |
| velpatasvir | N/A | 维帕他韦 |
| voxilaprevi | N/A | Sofosbuvir/velpatasvir/voxilaprevi |
EMA Name
Vosevi
Medicine Name
Vosevi
Aliases
N/ANo risk management plan link.
